Immune globulin subcutaneous, human-klhw - Biologic Drug Details

Summary for immune globulin subcutaneous, human-klhw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for immune globulin subcutaneous, human-klhw

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin subcutaneous, human-klhw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin subcutaneous, human-klhw Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin subcutaneous, human-klhw Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Human KHLW (Immune Globulin Subcutaneous)

Last updated: March 2, 2026

What is the Current Market Size and Growth Rate of Subcutaneous Immune Globulin?

The global market for subcutaneous immune globulin (SCIG) was valued at approximately $1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 9.6% from 2023 to 2030, reaching an estimated $2.4 billion by 2030 (Market Research Future, 2023).

Key Data Points:

• Market value in 2022: $1.2 billion
• Projected 2030 value: $2.4 billion
• CAGR (2023-2030): 9.6%

What Are the Major Drivers of Market Growth?

The growth in the immune globulin subcutaneous segment is driven by several factors:

• Increasing Prevalence of Immunodeficiency Disorders: Primary immunodeficiency diseases (PIDD) incidence is approximately 1 in 10,000 to 1 in 20,000 live births globally. This demographic is expanding with improved awareness and diagnostic techniques.

• Shift from Intravenous to Subcutaneous Administration: SCIG offers benefits including self-administration at home, reduced infusion-related reactions, and steady serum IgG levels, leading to higher patient compliance.

• Aging Population: Elderly populations have a higher incidence of secondary immunodeficiency due to comorbidities and immunosuppressive therapies, boosting demand.

• COVID-19 Impact: The pandemic emphasized the need for immune support therapies, accelerating adoption of immunoglobulin products.

• Regulatory Approvals and Expanded Indications: Increased approvals for SCIG in secondary immunodeficiency conditions expand the market scope.

What Are the Leading Players and Their Market Shares?

The industry landscape is dominated by key manufacturers, with a fragmented but consolidating market:

Company	Product Focus	Market Share (2022)	Key Notes
Grifols	Hizentra	~35%	First to market with SCIG; broad distribution network
CSL Behring	Vivaglobin	~25%	Extensive global reach; multiple indications
Octapharma	Octagam SC	~15%	Growing presence in North America and Europe
Others	Various brands	~25%	Niche and emerging players

Note: Market share estimates are approximate due to limited public disclosures.

How Do Regulatory and Pricing Policies Impact Financial Trajectory?

• Regulatory Approvals: Increased approvals for SCIG in various indications expand revenue streams. The US FDA has approved several formulations for primary and secondary immunodeficiencies.

• Pricing Strategies: Reimbursement policies differ globally. In the US, reimbursements from Medicare and Medicaid influence pricing, while in Europe, national health systems set prices. Pricing volatility impacts revenue projections.

• Patent Expirations: The expiration of key patents (e.g., Hizentra in 2025) could lead to generic competition, pressuring prices and margins.

• Cost of Goods Sold (COGS): Manufacturing costs, driven by plasma collection and purification processes, influence profit margins.

What Is the Financial Outlook and Investment Opportunity?

• Revenue Projections: Global revenues forecast to double by 2030, assuming steady market penetration and technological improvements.

• Profitability: Leading companies report gross margins around 30%-40%, with profit margins influenced by R&D, distribution, and regulatory compliance costs.

• Research & Development (R&D): Investments in next-generation formulations, stability, and subcutaneous delivery innovations remain high, aiming to extend product lifecycle and enhance patient outcomes.

• Emerging Markets: Rapid expansion in Asia and Latin America presents significant revenue potential, though regulatory and infrastructural challenges persist.

What Are the Critical Risks and Barriers?

• Manufacturing Constraints: Plasma component availability impacts production scalability.

• Market Entry Barriers: High clinical and regulatory standards slow new entrants.

• Competitive Pressure: Innovations in alternative therapies such as monoclonal antibodies and gene therapies may restrict market growth.

• Pricing Pressure: Payer negotiations and reimbursement caps threaten profit margins.

Summary of Key Financial Indicators (2022–2030)

Indicator	2022	2030 (Projected)
Market Value	$1.2 billion	$2.4 billion
CAGR	—	9.6%
Key Player Revenue (estimated)	multiple billion-dollar revenues	Incremental increases aligned with market growth
Gross Margins	30-40%	Stable, with potential compression due to patent cliffs and pricing pressures

---

Key Takeaways

• The subcutaneous immune globulin market is expanding rapidly, driven by increased demand for patient-friendly administration and therapeutic applications.
• Major companies hold significant market shares, with growth prospects from emerging markets and expanded indications.
• Regulatory environments and pricing policies influence financial performance directly.
• Innovations aimed at improved formulations and delivery methods are critical to sustaining competitive advantage.
• Market risks include manufacturing constraints, competitive threats, and reimbursement challenges.

---

FAQs

1. What is the impact of patent expirations on the human KHLW market? Patent expirations, projected around 2025 for leading products like Hizentra, may lead to generic competition, reducing prices and margins but also providing opportunities for biosimilar entrants.

2. How does the shift to subcutaneous formulation affect patient compliance? SCIG allows self-administration at home, reduces infusion frequency, and minimizes adverse reactions, leading to improved adherence and quality of life.

3. Which regions represent the fastest growth opportunities? Asia-Pacific and Latin America exhibit high growth potential due to increasing healthcare infrastructure and rising disease prevalence, despite facing regulatory and infrastructural hurdles.

4. How are new product developments influencing market dynamics? Innovations in stable, less invasive formulations and continuous infusion devices enable companies to capture higher market share and expand indications.

5. What are the typical profit margins for companies in this space? Gross margins range from 30% to 40%, influenced by COGS, R&D expenditure, and pricing environment.

---

References

[1] Market Research Future. (2023). Global immune globulin market outlook. Retrieved from https://www.marketresearchfuture.com

[2] Grand View Research. (2022). Subcutaneous immunoglobulin market analysis. Retrieved from https://www.grandviewresearch.com

[3] U.S. Food and Drug Administration. (2022). Approvals of immunoglobulin products. Retrieved from https://www.fda.gov

[4] Statista. (2023). Immunoglobulin market revenue forecast. Retrieved from https://www.statista.com

[5] IQVIA. (2022). Global plasma and immunoglobulin industry report. Retrieved from https://www.iqvia.com